Epigenetic and immune drugs join forces against tough tumors
NCT ID NCT04705818
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 30 times
Summary
This completed Phase 2 trial tested whether combining an immunotherapy drug (durvalumab) with an epigenetic drug (tazemetostat) can control advanced solid tumors like pancreatic, colorectal, and soft-tissue sarcoma. The study enrolled 164 adults and measured how well the combo shrank or stabilized tumors. The goal is to find a new way to treat cancers that don't respond to standard therapies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
CHRU Brest
Brest, 29200, France
-
CHU Poitiers
Poitiers, 86000, France
-
Institut Bergonie
Bordeaux, 33076, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
durvalumab and tazemetostat
What this could lead to
If successful, this combination could offer a new treatment option for several hard-to-treat cancers, potentially slowing or stopping tumor growth.
What could go wrong
This is a Phase 2 trial with modest enrollment (164 participants). The results may not apply to all cancer types, and side effects from the drug combination could limit its use.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.